North American Pharmaceutical was Mckesson’s largest segment in fiscal 2026, bringing in $338.25B of $403.99B (84%).
| Segment | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| North American Pharmaceutical | — | $261.37B | $305.61B | $338.25B | |||||||||||||
| U.S. Pharmaceutical | $240.62B | — | — | — | |||||||||||||
| Distribution Solutions | — | — | — | — | |||||||||||||
| North America Distribution & Services | — | — | — | — | |||||||||||||
| U.S. Pharmaceutical & Specialty Solutions | — | — | — | — | |||||||||||||
| Distribution Solutions - Direct Distribution & Services | — | — | — | — | |||||||||||||
| Oncology Multispecialty | — | $30.49B | $36.86B | $48.42B | |||||||||||||
| International | $20.60B | — | — | — | |||||||||||||
| European Pharmaceutical Solutions | — | — | — | — | |||||||||||||
| Distribution Solutions Sales To Customers Warehouses | — | — | — | — | |||||||||||||
| Distribution Solutions - Sales To Customers' Warehouses | — | — | — | — | |||||||||||||
| Other | — | — | — | — | |||||||||||||
| Medical-Surgical Solutions | $11.11B | $11.31B | $11.38B | $11.51B | |||||||||||||
| Distribution Solutions - Canada Pharmaceutical Distribution & Services | — | — | — | — | |||||||||||||
| Prescription Technology Solutions | $4.39B | $4.77B | $5.22B | $5.81B | |||||||||||||
| Medical Surgical Distribution & Services | — | — | — | — | |||||||||||||
| Distribution Solutions - Medical Surgical Distribution & Services | — | — | — | — | |||||||||||||
| Distribution Solutions - Medical-Surgical Distribution & Services | — | — | — | — | |||||||||||||
| Technology Solutions | — | — | — | — | |||||||||||||
| Technology Solutions - Services | — | — | — | — | |||||||||||||
| Technology Solutions - Software & Software Systems | — | — | — | — | |||||||||||||
| Technology Solutions - Hardware | — | — | — | — | |||||||||||||
| Total | $276.71B | $307.94B | $359.07B | $403.99B |
Mckesson brought in $403.99B from its four segments in fiscal 2026, the year ended March 31, 2026. That was up 12.5% from $359.07B in fiscal 2025. North American Pharmaceutical was the largest at $338.25B (83.7%), ahead of Oncology Multispecialty at $48.42B (12.0%) and Medical-Surgical Solutions at $11.51B (2.8%). The remaining segment, Prescription Technology Solutions, brought in $5.81B.
Compared with fiscal 2025, Oncology Multispecialty grew fastest, up 31.4% to $48.42B. Every segment above 2% of revenue grew.
Mckesson began breaking out North American Pharmaceutical in fiscal 2024 and Oncology Multispecialty in fiscal 2024. Mckesson stopped reporting U.S. Pharmaceutical ($240.62B in fiscal 2023) and International ($20.60B in fiscal 2023) as separate segments.
United States was Mckesson’s largest region in fiscal 2018, bringing in $169.94B of $208.36B (82%).
| Geography | FY 2009 | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $142.81B | $158.26B | $164.43B | $169.94B | ||||||
| Revenues | — | — | — | — | ||||||
| Foreign | $36.24B | $32.63B | $34.11B | $38.41B | ||||||
| Other | — | — | — | — | ||||||
| International | — | — | — | — | ||||||
| Total | $179.05B | $190.88B | $198.53B | $208.36B |
Mckesson brought in $208.36B from its two regions in fiscal 2018, the year ended March 31, 2018. That was up 4.9% from $198.53B in fiscal 2017. United States was the largest at $169.94B (81.6%), ahead of Foreign at $38.41B (18.4%).
Compared with fiscal 2017, Foreign grew 12.6% to $38.41B and United States grew 3.4% to $169.94B. From fiscal 2015 to 2018, combined revenue from these regions grew from $179.05B to $208.36B, a compound annual growth rate of 5.2%. United States' share of the total rose from 79.8% to 81.6%.
Mckesson (MCK) reports its revenue by segment and by geography. In fiscal 2026, North American Pharmaceutical was its largest segment, bringing in $338.25B (83.7% of the total), followed by Oncology Multispecialty at $48.42B (12.0%).
North American Pharmaceutical was Mckesson's largest segment in fiscal 2026, bringing in $338.25B, or 83.7% of the $403.99B total across its four segments.
United States was Mckesson's largest region in fiscal 2018, bringing in $169.94B, or 81.6% of the $208.36B total across its two regions.
Among Mckesson's segments that make up at least 2% of revenue, Oncology Multispecialty grew fastest in fiscal 2026, up 31.4% from $36.86B to $48.42B.
Every figure comes from Mckesson's annual financial filings, as reported. Each line keeps the name Mckesson gives it, and years follow its fiscal calendar.
Mckesson's revenue by segment goes back to fiscal 2010, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.